drugset / Trial / NCT00746317
A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.
Timeline
- Start
- 2008-09
- Primary completion
- 2010-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Codrituzumab | Monoclonal antibody | — | Intravenous |